Omar Zaher
Curriculum vitae
Since 01/2024: Doctoral student Clinical Pharmacy, Saarland University, Saarbrücken
06/2021 – 08/2021: Internship, Pharmacometrics research group, Uppsala University, Sweden
09/2020 – 08/2022: Master of pharmaceutical modeling, Uppsala University, Sweden
08/2018 – 08/2020: Senior product specialist, Sanofi Genzyme, Saudi-Arabia
06/2011 – 06/2018: Neurology product specialist, Biogen, Ägypten, Saudi-Arabia
01/2010 – 05/2011: Oncology medical representative, Hospira, Egypt
09/2005 – 06/2009: Pharmacy studies, Alexandria University, Faculty of pharmacy, Egypt
Manuscripts
Zaher O, Selzer D, Loer H, Neuschwender F, Steinbauer FF, Dings C, Rüdesheim S, Bragazzi NL, Walle N, Doerr AA, Peters B, Schwab M, Laschke MW, Menger MD, Schmidt PH, Meyer MR, Schaefer N, Lehr T. Physiologically based pharmacokinetic modeling as a translational tool in forensic toxicology: from pig to human synthetic cannabinoid toxicokinetics using 5F-Cumyl-P7AICA and its major metabolite as a case study. Arch Toxicol. 2026. doi:10.1007/s00204-026-04613-7 Walle N, Dings C, Zaher O, Doerr AA, Peters B, Laschke MW, Lehr T, Menger MD, Schmidt PH, Meyer MR, Schaefer N. Does a carboxamide moiety alter the toxicokinetics of synthetic cannabinoids? A study after pulmonary and intravenous administration of cumyl-5F-P7AICA to pigs. Arch Toxicol. 2025. doi:10.1007/s00204-024-03906-z Doerr AA, Dings C, Zaher O, Nordmeier F, Walle N, Laschke MW, Menger MD, Schmidt PH, Meyer MR, Lehr T, Schaefer N. Toxicokinetic modelling of the synthetic cannabinoid 5F-MDMB-P7AICA and its main metabolite in pigs following pulmonary administration. Br J Clin Pharmacol. 2024. doi:10.1111/bcp.16340 Centanni M, Zaher O, Elhad D, Karlsson MO, Friberg LF. Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children. Cancer Chemother Pharmacol. 2024. doi:10.1007/s00280-024-04678-0 |
